Cargando…
Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost
In CD34+ cells mobilization of patients with multiple myeloma (MM), the use of Cyclophosphamide (CTX) at a dose of 2 g/m(2) has low efficacy although also lower toxicity. The suboptimal mobilizing effect of low-dose CTX, however, may be overcome by plerixafor (PLX) on demand. We conducted a prospect...
Autores principales: | Milone, Giuseppe, Conticello, Concetta, Leotta, Salvatore, Michieli, Maria Grazia, Martino, Massimo, Marco, Anna Lia Di, Spadaro, Andrea, Cupri, Alessandra, Condorelli, Annalisa, Milone, Giulio Antonio, Markovic, Uros, Sciortino, Roberta, Schininà, Giovanni, Moschetti, Gaetano, Villari, Loredana, Saccardi, Riccardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649636/ https://www.ncbi.nlm.nih.gov/pubmed/33204611 http://dx.doi.org/10.1016/j.lrr.2020.100227 |
Ejemplares similares
-
Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives
por: Leotta, Salvatore, et al.
Publicado: (2022) -
Preliminary Results of a Combined Score Based on sIL2-Rα and TIM-3 Levels Assayed Early After Hematopoietic Transplantation
por: Leotta, Salvatore, et al.
Publicado: (2020) -
Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis
por: Lazzaro, Carlo, et al.
Publicado: (2021) -
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
por: Duminuco, Andrea, et al.
Publicado: (2023) -
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology
por: Milone, Giuseppe, et al.
Publicado: (2022)